Profound Medical’s TULSA Procedure Gains Recognition at RSNA

Profound Medical ( (TSE:PRN) ) has issued an announcement.

Profound Medical Corp. announced that Dr. Pejman Ghanouni from Stanford University received the Cum Laude award at the RSNA Annual Meeting for his presentation on the CAPTAIN trial, which compares the TULSA Procedure to robotic radical prostatectomy. The TULSA Procedure has shown significant advantages in recovery time and patient experience, offering a promising alternative to traditional prostate cancer treatments. This achievement highlights the potential of TULSA-PRO as a mainstream treatment option, enhancing Profound Medical’s position in the medical device industry.

The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.

Spark’s Take on TSE:PRN Stock

According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.

Profound Medical’s stock score reflects the company’s strong revenue growth and strategic potential, balanced by operational inefficiencies and financial challenges. Technical indicators suggest caution due to bearish trends, while valuation remains a concern with negative earnings. Positive earnings call sentiment and future growth prospects are encouraging, yet immediate operational improvements are necessary for sustained success.

To see Spark’s full report on TSE:PRN stock, click here.

More about Profound Medical

Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company is focused on commercializing TULSA-PRO, a technology that integrates real-time MRI, AI-enhanced planning, and robotically-driven transurethral ultrasound for precise prostate therapy.

Average Trading Volume: 21,362

Technical Sentiment Signal: Buy

Current Market Cap: C$258.2M

Learn more about PRN stock on TipRanks’ Stock Analysis page.